Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

In the present study, we evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin lymphoma (cHL). In this phase 2 study, patients with chemotherapy-naive, advanced-stage cHL were treate...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Younes, Anas, Oki, Yasuhiro, McLaughlin, Peter, Copeland, Amanda R., Goy, Andre, Pro, Barbara, Feng, Lei, Yuan, Ying, Chuang, Hubert H., Macapinlac, Homer A., Hagemeister, Fredrick, Romaguera, Jorge, Samaniego, Felipe, Fanale, Michelle A., Dabaja, Bouthaina Shbib, Rodriguez, Maria A., Dang, Nam, Kwak, Larry W., Neelapu, Sattva S., Fayad, Luis E.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2012
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3359733/
https://ncbi.nlm.nih.gov/pubmed/22371887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-405456
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items